Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types

The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials

Sun's cancer drug shines delivering 50% response rate with long-lasting tumor control

These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

Nuvation Bio secures global rights to promising brain tumor drug Safusidenib, expands Phase 3 study to Japan

Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan

Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema

Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors

Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile

Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors

Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial

The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival

FDA nod to Koselugo for adults with Rare NF1 tumors, expanding life-changing treatment

Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors

Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile